RAGE 229

• Description :

  RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE (ctRAGE) and Diaphanous-1 (DIAPH1) [1].

• UNSPSC :

  12352005

• Target :

  Transmembrane Glycoprotein

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/rage-229.html

• Concentration :

  10mM

• Purity :

  99.89

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  CC(NC1=CC=C(C2=NC3=CC(C#N)=CC=C3C(CN4CCOCC4)=C2)C=C1)=O

• Molecular Formula :

  C23H22N4O2

• Molecular Weight :

  386.45

• References & Citations :

  [1]Michaele B Manigrasso, et al. Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Sci Transl Med. 2021 Nov 24;13 (621) :eabf7084.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2143072-85-7]